---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-256682"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:39:57.379426+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences reports positive target engagement data for WVE-007 in obesity; Activin E reductions up to 85%

## Summary
- WVE-007 achieved Activin E reductions of 85% (400mg), 75% (240mg), 56% (75mg) at one month, all highly significant (p<0.0001).
- 75mg cohort showed durable reduction through 6 months, supporting once or twice yearly dosing.
- WVE-007 safe and well tolerated; independent data monitoring committee supported dose expansion and escalation.
- Multiple clinical data updates including body composition and weight expected starting 4Q2025.
- Announced WVE-008 RNA editing candidate for PNPLA3 liver disease; CTA filing anticipated in 2026.

## SEC filing metadata
- accession: 0001193125-25-256682
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312525256682/0001193125-25-256682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312525256682/d95356d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-256682
- JSON: https://secwatch.observer/filing/0001193125-25-256682.json
- Plain text: https://secwatch.observer/filing/0001193125-25-256682.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.